When investigators search for CJC-1295 DAC pharmacy standards, they are typically evaluating analytical purity, sterile manufacturing practices, and structural integrity for preclinical studies. CJC-1295 with Drug Affinity Complex (DAC) is a long-acting growth-hormone-releasing hormone (GHRH) analog synthesized exclusively for laboratory research use to study sustained GH and downstream IGF-1 activation in cellular and animal models.
When investigators search for CJC-1295 DAC pharmacy standards, they are typically evaluating analytical purity, sterile manufacturing practices, and structural integrity for preclinical studies. CJC-1295 with Drug Affinity Complex (DAC) is a long-acting growth-hormone-releasing hormone (GHRH) analog synthesized exclusively for laboratory research use to study sustained GH and downstream IGF-1 activation in cellular and animal models.
In the context of biochemical research, queries surrounding 'CJC-1295 DAC pharmacy' reflect a demand for pharmaceutical-grade manufacturing rigor—specifically high-performance liquid chromatography (HPLC) purification, mass spectrometry validation, and low endotoxin thresholds. While compounding pharmacies operate under human clinical regulations, research institutions require analytical-grade research-grade CJC-1295 DAC that adheres to identical chemical identity and purity metrics without clinical additives or formulation agents.
CJC-1295 DAC is a synthetic 29-amino-acid peptide derived from human GHRH(1-29). By incorporating a Drug Affinity Complex (DAC) moiety—specifically a reactive maleimidopropionic acid group attached via a linker to the C-terminal lysine—the molecule rapidly binds to endogenously circulating serum albumin upon administration in laboratory animal models. This bioconjugation extends the terminal elimination half-life from minutes to several days, enabling researchers to maintain steady baseline GHRH receptor occupancy in longitudinal preclinical protocols.
The primary sequence of CJC-1295 modified with DAC features specific amino acid substitutions designed to resist enzymatic degradation. In natural GHRH(1-29), dipeptidyl peptidase IV (DPP-IV) rapidly cleaves the peptide between the Ala-2 and Asp-3 residues, inactivating the hormone within 5 to 12 minutes in vivo. CJC-1295 replaces Ala-2 with D-alanine, Glutamine-8 with Glutamine, Asparagine-15 with Alanine, and Lysine-27 with Arginine.
These structural modifications protect the core catalytic sequence while preserving high binding affinity for the pituitary GHRH receptor. The addition of the DAC link at Lys-30 enables covalent bonding to the cysteine-34 residue of serum albumin. In animal studies, this albumin-bound complex remains biologically active, shielding the peptide from renal clearance and proteolysis. Researchers utilizing our preclinical research database regularly examine these pharmacokinetic parameters to model extended endocrine signaling.
CJC-1295 DAC acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) expressed on anterior pituitary somatotropes. Receptor binding activates the Gs alpha subunit, triggering adenylate cyclase to convert ATP to cyclic adenosine monophosphate (cAMP). Increased intracellular cAMP levels activate protein kinase A (PKA), which subsequently opens voltage-gated calcium channels, driving the transcription and exocytosis of growth hormone (GH).
Unlike native GHRH, which produces acute, transient GH spikes, CJC-1295 DAC maintains continuous receptor engagement. In vivo animal assays demonstrate that sustained GHRHR activation elevates total integrated GH secretion without entirely suppressing the physiological pulsatile pattern driven by endogenous somatostatin release. This steady GH elevation leads to sustained hepatic production of insulin-like growth factor 1 (IGF-1), making the compound a central focus in tissue repair, cell proliferation, and metabolic signaling studies.
Preclinical literature demonstrates that continuous GHRH receptor stimulation via CJC-1295 DAC influences multiple physiological pathways in animal models. In rodent models of musculoskeletal injury, sustained elevations of circulating IGF-1 correlate with enhanced satellite cell activation, accelerated myofibrillar protein synthesis, and increased collagen deposition within connective tissue matrices.
Furthermore, preclinical investigations into body composition show that long-acting GHRH analogs shift metabolic substrate utilization toward lipolysis. In high-fat diet rodent models, administration of CJC-1295 DAC was associated with reduced visceral adiposity, improved insulin sensitivity markers, and elevated basal nitrogen retention. These findings provide baseline data for ongoing studies exploring age-related somatopause models and metabolic homeostasis.
When designing comparative endocrine protocols, investigators often evaluate CJC-1295 DAC alongside other growth hormone secretagogues to determine the optimal kinetic profile for their experimental model. The fundamental distinction between these peptides lies in their receptor specificity, half-life, and peak-to-trough ratio.
While CJC-1295 DAC yields prolonged, elevated basal GH levels over 6 to 8 days in animal models, CJC-1295 without DAC (Mod GRF 1-29) provides a short half-life (~30 minutes) designed to mimic natural, acute physiological pulses. In contrast, ghrelin receptor (GHS-R1a) agonists like Ipamorelin stimulate GH release via an entirely distinct intracellular cascade, operating independently of the GHRH receptor. Other classical GHRH analogs such as Sermorelin retain the native sequence structure with rapid clearance, whereas specialized analogs like Tesamorelin feature a trans-3-hexenoic acid modification tailored for specific hepatic lipolysis pathways.
To achieve research results comparable to institutional pharmacy-grade standards, laboratories must verify peptide purity through rigorous physical testing. Impurities, truncated sequences, or residual TFA (trifluoroacetic acid) can alter receptor binding affinity and yield artifactual cellular responses in vitro.
Every lot of CJC-1295 DAC supplied by PX1 Research undergoes rigorous analytical verification: Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) ensures purity levels exceeding 98.0%, confirming the absence of failure sequences. Electrospray Ionization Mass Spectrometry (ESI-MS) verifies precise molecular mass (C152H252N44O42, theoretical MW: 3288.7 g/mol). Additionally, Limulus Amebocyte Lysate (LAL) testing guarantees endotoxin content remains strictly below 0.1 EU/mg, preventing unspecific inflammatory responses in cellular and animal culture assays.
CJC-1295 DAC is supplied as a lyophilized (freeze-dried) cake to ensure long-term chemical stability. Reconstitution must be performed in a sterile laboratory environment using appropriate aseptic technique. For standard laboratory applications, Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Normal Saline (0.9% NaCl) is added gently down the glass vial wall.
To prevent mechanical shear stress and peptide degradation, the vial should be gently swirled rather than vigorously shaken. Full dissolution typically occurs within 30 to 60 seconds. Researchers calculating concentration parameters for micro-dosing pumps or in vitro assay wells should account for total liquid volume added relative to the milligram mass contained in the vial (e.g., 2 mg lyophilized peptide in 2 mL solvent yields a 1.0 mg/mL concentration).
Lyophilized CJC-1295 DAC exhibits superior thermal stability when stored at lower temperatures. Upon receipt, sealed vials should be stored at -20°C (-4°F) or -80°C (-112°F) in a manual defrost freezer, shielded from direct light. Under these conditions, the un-reconstituted peptide maintains chemical stability for up to 24 months.
Once reconstituted into aqueous solution, the peptide becomes susceptible to hydrolytic cleavage over extended timeframes. Reconstituted vials must be stored at 2°C to 8°C (36°F to 46°F) and utilized within 30 days. Multiple freeze-thaw cycles of liquid aliquots should be strictly avoided, as phase transitions induce structural aggregation and loss of biological activity.
PX1 Research serves as a trusted primary supplier for academic, clinical trial, and industrial research laboratories nationwide. All peptides are synthesized in state-of-the-art, GMP-compliant facilities located within the United States. We maintain strict compliance with ISO 17025 laboratory standards to ensure every batch meets exacting pharmaceutical-grade benchmarks.
Principal investigators and research procurement teams establishing institutional research accounts gain direct access to lot-specific Certificates of Analysis (COAs), complete HPLC chromatograms, and mass spec data files. Orders ship same-day (Monday through Friday) from our distribution hubs in California and Arizona, utilizing temperature-monitored packaging protocols to preserve compound integrity during transit.
What is the difference between CJC-1295 DAC and non-DAC CJC-1295?
CJC-1295 DAC contains a Drug Affinity Complex that covalently binds to serum albumin in vivo, extending its biological half-life to approximately 6 to 8 days in preclinical models. CJC-1295 without DAC (Mod GRF 1-29) lacks this complex, resulting in a short half-life of roughly 30 minutes that induces acute, rapid GH pulses.
How does PX1 Research verify the purity of CJC-1295 DAC?
Every lot undergoes independent ISO 17025 third-party laboratory testing using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity (≥98%) and Electrospray Ionization Mass Spectrometry (ESI-MS) for molecular mass verification. Endotoxin levels are quantified via LAL testing to ensure levels under 0.1 EU/mg.
Is CJC-1295 DAC available from human compounding pharmacies?
Regulatory shifts in recent years have altered compounding pharmacy regulations regarding long-acting peptide analogs. PX1 Research supplies high-purity, analytical-grade CJC-1295 DAC strictly designated for laboratory research, in vitro experiments, and preclinical animal studies—not for human clinical administration.
What solvent is recommended for reconstituting CJC-1295 DAC in benchwork?
Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile 0.9% sodium chloride solution is recommended for reconstitution. The selection depends on the duration and specific requirements of the planned assay.
What is the primary mechanism of action of CJC-1295 DAC?
CJC-1295 DAC acts as a continuous agonist at the GHRH receptor on pituitary somatotropes. Receptor activation elevates cyclic AMP (cAMP) via Gs protein signaling, driving transcription and secretion of endogenous growth hormone (GH) and downstream hepatic IGF-1.
How should lyophilized CJC-1295 DAC be stored upon arrival?
Lyophilized vials should be stored at -20°C or colder in a desiccated, light-protected environment. Reconstituted liquid solutions should be kept refrigerated at 2°C–8°C and used within 30 days.
Are batch-specific Certificates of Analysis (COA) provided with orders?
Yes. Every shipment from PX1 Research includes access to the lot-specific Certificate of Analysis detailing HPLC purity percentage, mass spec verification, and endotoxin assay results.
Where are PX1 Research peptides manufactured and shipped from?
All PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities and shipped directly from distribution centers in California and Arizona with same-day dispatch for orders placed Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.